Home › Acute Biphenotypic Leukemia › Ohio › Akron
Acute Biphenotypic Leukemia clinical trials in Akron, OH
4 studies for Acute Biphenotypic Leukemia are looking for participants at sites in and around Akron (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Children's Hospital Medical Center of Akron, Akron
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Children's Hospital Medical Center of Akron, Akron
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Children's Hospital Medical Center of Akron, Akron
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RecruitingPhase 1/2
- Gabrail Cancer Center Research,, Canton · 21 mi away
Acute Biphenotypic Leukemia trials in other cities
- Seattle, WA15 studies
- Houston, TX11 studies
- New York City, NY10 studies
- Atlanta, GA8 studies
- Durham, NC8 studies
- Chicago, IL7 studies
- Memphis, TN7 studies
- Baldwin Park, CA6 studies
- Philadelphia, PA6 studies
- Los Angeles, CA6 studies
- Dallas, TX6 studies
- Charlotte, NC6 studies
Other studies in Akron
- Non-Small Cell Lung Cancer22 studies
- Lung Cancer16 studies
- Cancer (all types)14 studies
- Breast Cancer13 studies
- Prostate Cancer9 studies
- Metastatic Cancer8 studies
- Colorectal Cancer8 studies
- Melanoma8 studies
- Acute Myeloid Leukemia8 studies
- Small Cell Lung Cancer8 studies
- Endometrial Cancer7 studies
- Steatotic Liver Disease7 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.